The approval of edaravone for amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease by the FDA will benefit patients with the motor neuron disease.
- Amyotrophic lateral sclerosis is a progressive neurological disease that affects nerves supplying to voluntary muscles
- Most cases are sporadic, while some are inherited
- Edaravone has been recently approved by the FDA for this condition
The FDA has recently approved another drug called edaravone for the treatment of ALS. Edaravone reduces oxidative stress, which can damage nerves, and slows down the progression of the condition.
Edaravone was previously approved in Japan and South Korea in 2015 for ALS. It has been found to reduce progression of symptoms when administered intravenously in the prescribed doses. It is administered in cycles, initially daily for 14 days, followed by a 14-day break, with doses in later cycles limited to days 10 and 14, with 14-day breaks.
Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research, said, “After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States.”
“This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option.”
Amyotrophic Lateral Sclerosis (ALS)
ALS currently does not have a cure, though patients are provided with supportive treatments, and medications to treat symptoms like muscle pain and excess salivation. Physical therapy and speech therapy help the patient to cope with the problems they face as the disease progresses. Advanced cases require nutritional and breathing support.
References:
- What is amyotrophic lateral sclerosis? - (https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet)
- FDA approves drug to treat ALS - (https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm557102.htm)